The Covid-19 pandemic has changed the game for Pfizer’s vaccines division. The Comirnaty, developed with BioNTech, put Pfizer back on the throne of global pharmacy. In 2022, this vaccine alone generated 37.8 billion dollars (just over 35 billion euros) in sales for the American laboratory, out of a total turnover of 100.3 billion dollars (93.5 Billions of Euro’s). Pfizer no longer details the revenues of its vaccines division. In 2019, before the pandemic, turnover was around 6.5 billion dollars (6 billion euros). In 2022, excluding Comirnaty, revenues related to other vaccines were around 7 billion dollars (6.5 billion euros approximately), according to the data noted in the last annual report. The American laboratory also does not give a financial perspective for its vaccines. On the other hand, the pipeline is full of projects, some of which might be completed very quickly. About ten marketings are planned until 2025-2026.
Pfizer mobilized on RSV and bronchiolitis
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Login
VOS INDICES
source
Selected for you
